Evaluating neoadjuvant therapy effectiveness on systemic disease: Use of a prostatic-specific membrane reverse transcription polymerase chain reaction

Sensitivity or specificity of reverse transcriptase-polymerase chain reaction assays: The real challenge for molecular staging of prostatic carcinomas

“…Our hypothesis has been confirmed by Su et al (1997): (3) (Israeli et al, 1994;Loric et al, 1995). An understanding of these observations would require hard data highlighting the influence of hormone therapy on the detection rate of respective transcripts, as well as on the biology of circulating cells in cancer patients.…”

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

“…26,27 Such PSM-containing cells apparently spill into the circulation during radical prostatectomy, 28 but decline in number after androgen deprivation therapy. 7,29 Antibody-radionucleotide conjugates to PSM have been used to successfully localize metastatic prostate carcinoma in animals and humans 18,19 and to treat human cancer in nude mice. 2 We found consistent PSM immunoreactivity in high grade PIN and prostate adenocarcinoma.…”

Detection of disseminated prostate cells by reverse transcription-polymerase chain reaction (RT-PCR): Technical and clinical aspects

“…Because PSMA is not regulated by androgens, PSMA RT-PCR was used in one study to test the effects of hormone-ablation therapy on the presence of circulating prostate cells (Su et al, 1997); 17% of pT2 and 20% of pT3 patients undergoing neoadjuvant therapy (ADT) were positive, vs. 40% and 36% of control pT2 and pT3 patients, respectively. These results indicate that preoperative ADT does indeed decrease the number of circulating PSMA-positive cells, and thus may decrease the risk of metastasis.…”